From the 1Columbus Center for Women’s Health Research, Columbus, OH; and 2The North American Menopause Society, Mayfield Heights, OH.
Received July 9, 2014; revised and accepted July 9, 2014.
Vulvovaginal Atrophy Terminology Consensus Conference Panel:
David Portman, MD (Co-Chair); Margery Gass, MD, NCMP (Co-Chair); Sheryl Kingsberg, PhD (Conference Moderator); David Archer, MD, NCMP; Gloria Bachmann, MD; Lara Burrows, MD, MSc; Murray Freedman, MS, MD; Andrew Goldstein, MD; Irwin Goldstein, MD; Debra Heller; MD, Cheryl Iglesia, MD; Risa Kagan, MD, NCMP; Susan Kellogg Spadt, PhD, CRNP; Michael Krychman, MD; Lila Nachtigall, MD, NCMP; Rossella Nappi, MD, PhD; JoAnn Pinkerton, MD, NCMP; Jan Shifren, MD, NCMP; James Simon, MD, NCMP; Cynthia Stuenkel, MD, NCMP.
This article is being simultaneously published in the journals Climacteric, The Journal of Sexual Medicine, Maturitas, and Menopause, The Journal of The North American Menopause Society.
Funding/support: The Consensus Conference was sponsored by unrestricted educational grants from Apricus Biosciences; Bayer; Novo Nordisk; Shionogi; Tara Allmen, MD; Lil’ Drug Store; Warner Chilcott; and Women’s Initiative on Sexual Health (WISH).
Financial disclosure/conflicts of interest: M.L.S.G. reports no disclosures. D.P. reports research grants from Abbvie, Activas, Amneal, Bayer, Endoceutics, Noven, Palatin, Pfizer, QuatRx, Sun Pharmaceuticals, Teva, TherapeuticsMD; consultant for Activas, Noven, NovoNordisk, Palatin, Pfizer, Shionogi, Sprout, TherapeuticsMD; and has received payment for speaker’s bureau for Noven, Pfizer and Shionogi.
Address correspondence to: David J. Portman, MD, Director, Columbus Center for Women’s Health Research, 99 North Brice Road, Suite 120, Columbus, OH 43213. E-mail: [email protected]
